Update on the use of antihypertensive drugs in pregnancy.

As the most common medical disorder of pregnancy, hypertension is reported to complicate 1 in 10 pregnancies1,2 and affects an estimated 240 000 women in the United States each year.3 Antihypertensive treatment rationale in this group represents a departure from the nonpregnant adult Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines.4 First, during pregnancy, the priority regarding hypertension is in making the correct diagnosis, with the emphasis on distinguishing preexisting (chronic) from pregnancy induced (gestational hypertension and the syndrome of preeclampsia). Second, much of the obstetric literature distinguishes blood pressure (BP) levels as either mild (140 to 159/90 to 109 mm Hg) or severe (≥160/110 mm Hg), rather than as stages (as in Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; Table 1). Third, in contrast to hypertension guidelines in adults, which emphasize the importance of systolic BP, much of the obstetric literature focuses on diastolic rather than systolic BP, in part because of the lack of clinical trials to support one approach versus another. The focus of treatment is the 9 months of pregnancy, during which untreated mild-to-moderate hypertension is unlikely to lead to unfavorable long-term maternal outcomes. In this setting, antihypertensive agents are mainly used to prevent and treat severe hypertension; to prolong pregnancy for as long as safely possible, thereby maximizing the gestational age of the infant; and to minimize fetal exposure to medications that may have adverse effects. During pregnancy, the challenge is in deciding when to use antihypertensive medications and what level of BP to target. The choice of antihypertensive agents is less complex, because only a small proportion of currently available drugs have been adequately evaluated in pregnant women, and many others …

[1]  B. Carbonne,et al.  Nicardipine versus metoprolol in the treatment of hypertension during pregnancy: A randomized comparative trial , 1994, Obstetrics and gynecology.

[2]  B. Sibai,et al.  Mild gestational hypertension remote from term: progression and outcome. , 2001, American journal of obstetrics and gynecology.

[3]  A. Samadi,et al.  Maternal Hypertension and Associated Pregnancy Complications Among African‐American and Other Women in the united States , 1996, Obstetrics and gynecology.

[4]  B. Sibai,et al.  A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term , 1987, Obstetrics and gynecology.

[5]  E. Steegers,et al.  Nicardipine in pre‐eclamptic patients: placental transfer and disposition in breast milk , 2007, BJOG : an international journal of obstetrics and gynaecology.

[6]  E. Begg,et al.  Concentrations of beta-blocking drugs in human milk. , 1990, The Journal of pediatrics.

[7]  J. J. Buckley,et al.  Report of Three Cases , 1962 .

[8]  P. Fayers,et al.  Randomised controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy. , 1983, British medical journal.

[9]  D. Clark,et al.  PLACEBO-CONTROLLED TRIAL OF ATENOLOL IN TREATMENT OF PREGNANCY-ASSOCIATED HYPERTENSION , 1983, The Lancet.

[10]  E. Gallery,et al.  EXCRETION OF ANTIHYPERTENSIVE MEDICATION INTO HUMAN BREAST MILK: A SYSTEMATIC REVIEW , 2002, Hypertension in pregnancy.

[11]  L. Magee Drugs in pregnancy. Antihypertensives. , 2001, Best practice & research. Clinical obstetrics & gynaecology.

[12]  B. Sibai,et al.  A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. , 1990, American journal of obstetrics and gynecology.

[13]  N. Wasserstrum Nitroprusside in Preeclampsia Circulatory Distress and Paradoxical Bradycardia , 1991, Hypertension.

[14]  R. Newman,et al.  Hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies. , 1996, American journal of obstetrics and gynecology.

[15]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[16]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[17]  L. Magee,et al.  Fortnightly review: management of hypertension in pregnancy. , 1999, BMJ.

[18]  V. Paul,et al.  Effects of maternal labetalol on the newborn infant. , 1992, Indian pediatrics.

[19]  B. Carleton,et al.  Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. , 2005, American journal of obstetrics and gynecology.

[20]  R. Gratton,et al.  Felodipine use in pregnancy. Report of three cases. , 1997, The Journal of reproductive medicine.

[21]  D. Henderson-smart,et al.  Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. , 2018, The Cochrane database of systematic reviews.

[22]  L. Magee,et al.  Oral beta-blockers for mild to moderate hypertension during pregnancy. , 2003, The Cochrane database of systematic reviews.

[23]  J. Anthony,et al.  Hemodynamic Changes Associated With Intravenous Infusion of the Calcium Antagonist Verapamil in the Treatment of Severe Gestational Proteinuric Hypertension , 1990, Obstetrics and gynecology.

[24]  C. Redman,et al.  FETAL OUTCOME IN TRIAL OF ANTIHYPERTENSIVE TREATMENT IN PREGNANCY , 1976, The Lancet.

[25]  A. Sedman,et al.  Angiotensin-converting enzyme inhibitor fetopathy. , 1993, Journal of the American Society of Nephrology : JASN.

[26]  K. Maršál,et al.  Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study. , 1995, American journal of obstetrics and gynecology.

[27]  R. Peters,et al.  A case demonstrating possible initiation of chronic liver disease , 1974 .

[28]  P. Corvol,et al.  [Antihypertensive drugs during pregnancy]. , 1975, La Revue du praticien.

[29]  E. M. Symonds,et al.  The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. , 1989, British journal of obstetrics and gynaecology.

[30]  S. Bull,et al.  Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials. , 2000, European journal of obstetrics, gynecology, and reproductive biology.

[31]  FDA classification of drugs for teratogenic risk. Teratology Society Public Affairs Committee. , 1994, Teratology.

[32]  V. Apgar,et al.  DRUGS IN PREGNANCY. , 1965, JAMA.

[33]  H. Odendaal,et al.  Serotonin Antagonism and Serotonin Antagonists in Pregnancy: Role of Ketanserin , 2000, Obstetrical & gynecological survey.

[34]  S. Lurie,et al.  Nifedipine in the Treatment of Severe Preeclampsia , 1991, Obstetrics and gynecology.

[35]  C. Redman,et al.  Hypertension during pregnancy, with and without specific hypotensive treatment. II. The growth and development of the infant in the first year of life. , 1977, Early human development.

[36]  W. White Management of hypertension during lactation. , 1984, Hypertension.

[37]  E. Burgess,et al.  Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[38]  S. Hernández-Díaz,et al.  Major congenital malformations after first-trimester exposure to ACE inhibitors. , 2006, The New England journal of medicine.

[39]  R. Ehrenkranz,et al.  Nifedipine transfer into human milk. , 1989, The Journal of pediatrics.

[40]  K. Aleš Magnesium plus nifedipine. , 1990, American journal of obstetrics and gynecology.

[41]  G. Lip,et al.  Effect of atenolol on birth weight. , 1997, The American journal of cardiology.

[42]  M. Lambot,et al.  Angiotensin-II-receptor inhibitors in pregnancy , 2001, The Lancet.

[43]  D. Blondheim,et al.  Expert consensus document on management of cardiovascular diseases during pregnancy. , 2003, European heart journal.

[44]  S. Lindow,et al.  The effect of nifedipine on fetal umbilical artery Doppler waveforms in pregnancies complicated by hypertension. , 1991, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[45]  G. Norman,et al.  How medical students learn spatial anatomy , 2001, The Lancet.

[46]  N. Thompson,et al.  Pheochromocytoma and pregnancy: the epitome of high risk. , 1993, Surgery.

[47]  G Koren,et al.  Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis , 2000, The Lancet.

[48]  R. H. Philpott,et al.  Effect of dihydralazine on the fetus in the treatment of maternal hypertension. , 1980, Obstetrics and gynecology.

[49]  Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. , 2000, American journal of obstetrics and gynecology.

[50]  M. Hadders‐Algra,et al.  Is clonidine a behavioural teratogen in the human? , 1986, Early human development.

[51]  J. Umans Medications during pregnancy: antihypertensives and immunosuppressives. , 2007, Advances in chronic kidney disease.

[52]  C. Shoemaker,et al.  Sodium nitroprusside for control of severe hypertensive disease of pregnancy: a case report and discussion of potential toxicity. , 1984, American journal of obstetrics and gynecology.

[53]  A. Hagiwara,et al.  Losartan and fetal toxic effects , 2001, The Lancet.

[54]  L. Magee,et al.  Antihypertensive Medications in Management of Gestational Hypertension-Preeclampsia , 2005, Clinical obstetrics and gynecology.

[55]  J. Higgins,et al.  The detection, investigation and management of hypertension in pregnancy: full consensus statement , 2000, The Australian & New Zealand journal of obstetrics & gynaecology.

[56]  M. Thompson,et al.  Blood pressure in the puerperium. , 1986, Clinical science.

[57]  S. Malecha,et al.  Angiotensin Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Blockers (ARBs) and Lactation: An Update , 2000, Journal of human lactation : official journal of International Lactation Consultant Association.

[58]  S. Bull,et al.  The generalizability of trial data; a comparison of β-blocker trial participants with a prospective cohort of women taking β-blockers in pregnancy , 2001 .

[59]  A. Makris,et al.  Postpartum hypertension and nonsteroidal analgesia. , 2004, American journal of obstetrics and gynecology.

[60]  D. Henderson-smart,et al.  Drugs for treatment of very high blood pressure during pregnancy. , 2013, The Cochrane database of systematic reviews.

[61]  J. Martin,et al.  Stroke and Severe Preeclampsia and Eclampsia: A Paradigm Shift Focusing on Systolic Blood Pressure , 2005, Obstetrics and gynecology.

[62]  D. Arduini,et al.  Effects of nifedipine on umbilical artery velocity waveforms in healthy human fetuses. , 1987, Gynecologic and obstetric investigation.

[63]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, Journal of the American Medical Association (JAMA).

[64]  D. Henderson-smart,et al.  Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. , 2014, The Cochrane database of systematic reviews.

[65]  L. Magee,et al.  Prevention and treatment of postpartum hypertension. , 2005, The Cochrane database of systematic reviews.

[66]  H. V. van Geijn,et al.  Pharmacological treatment of severe hypertension in pregnancy and the role of serotonin(2)-receptor blockers. , 2001, European journal of obstetrics, gynecology, and reproductive biology.

[67]  G. H. Lambert,et al.  Transfer of drugs and other chemicals into human milk. , 2001, Pediatrics.

[68]  W. Hop,et al.  Morbidity and development in childhood of infants born after temporising treatment of early onset pre-eclampsia. , 2005, BJOG : an international journal of obstetrics and gynaecology.

[69]  Angiotensin-II-receptor inhibitors in pregnancy , 2001 .

[70]  L. Beilin,et al.  TREATMENT OF HYPERTENSION IN PREGNANCY WITH METHYLDOPA: BLOOD PRESSURE CONTROL AND SIDE EFFECTS , 1977, British journal of obstetrics and gynaecology.

[71]  Joshua R. Smith,et al.  Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[72]  D. M. Humphreys,et al.  Controlled trial of hypotensive agents in hypertension in pregnancy. , 1968, British heart journal.

[73]  E. Begg,et al.  Drugs in Human Milk , 1988, Clinical pharmacokinetics.

[74]  S. Kennedy,et al.  Atenolol in essential hypertension during pregnancy. , 1990, BMJ.

[75]  G. Breart,et al.  Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial , 1988, British journal of obstetrics and gynaecology.

[76]  J. Soustiel,et al.  The effect of isosorbide dinitrate, a donor of nitric oxide, on maternal cerebral blood flow in gestational hypertension and preeclampsia. , 2003, American journal of obstetrics and gynecology.

[77]  P. Lundborg,et al.  Classification of drugs for teratogenic risk , 2004, European Journal of Clinical Pharmacology.

[78]  R. Peto,et al.  Overview of randomised trials of diuretics in pregnancy. , 1985, British medical journal.

[79]  S. Montán,et al.  Effects of methyldopa on uteroplacental and fetal hemodynamics in pregnancy-induced hypertension. , 1993, American journal of obstetrics and gynecology.

[80]  E. Gallery,et al.  Antihypertensive treatment in pregnancy: analysis of different responses to oxprenolol and methyldopa. , 1985, British medical journal.

[81]  L. M. Mayorga,et al.  Magnesium Plus Nifedipine: Potentiation of Hypotensive Effect in Preeclampsia? , 1988, American journal of obstetrics and gynecology.

[82]  S. Lindow,et al.  The effect of sublingual nifedipine on uteroplacental blood flow in hypertensive pregnancy , 1988, British journal of obstetrics and gynaecology.

[83]  C. Redman,et al.  FINAL REPORT OF STUDY ON HYPERTENSION DURING PREGNANCY: THE EFFECTS OF SPECIFIC TREATMENT ON THE GROWTH AND DEVELOPMENT OF THE CHILDREN , 1982, The Lancet.

[84]  B. Corenblum,et al.  Spironolactone therapy during human pregnancy. , 1995, American journal of obstetrics and gynecology.

[85]  C. Redman,et al.  Hypertension during pregnancy, with and without specific hypotensive treatment. I. Perinatal factors and neonatal morbidity. , 1977, Early human development.

[86]  I. Marcovici Postpartum preeclampsia management with furosemide: a randomized clinical trial. , 2005, Obstetrics and gynecology.

[87]  R. Wurtman,et al.  Increased TRH content of the basal ganglia in Huntington's disease. , 1980, The New England journal of medicine.

[88]  Harpar S. Buttar An overview of the influence of ACE inhibitors on fetal-placental circulation and perinatal development , 1997, Molecular and Cellular Biochemistry.

[89]  L. Butters,et al.  First year of life after the use of atenolol in pregnancy associated hypertension. , 1984, Archives of disease in childhood.

[90]  R. Peters,et al.  Acute submassive hepatic necrosis due to methyldopa. A case demonstrating possible initiation of chronic liver disease. , 1974, Gastroenterology.

[91]  B. Sibai,et al.  Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. , 2007, American journal of obstetrics and gynecology.

[92]  Patrick G. Arbogast,et al.  Major congenital malformations after first-trimester exposure to ACE inhibitors , 2006 .

[93]  M. Nageotte,et al.  Fatal Fetal Outcome with the Combined Use of Valsartan and Atenolol , 2001, The Annals of pharmacotherapy.

[94]  M. de Swiet,et al.  The management of postpartum hypertension , 2002, BJOG : an international journal of obstetrics and gynaecology.

[95]  E. Shalev,et al.  The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade , 1994, British journal of obstetrics and gynaecology.

[96]  T. Sandritter,et al.  Principles of Drug Transfer into Breast Milk and Drug Disposition in the Nursing Infant , 1997, Journal of human lactation : official journal of International Lactation Consultant Association.

[97]  A. Pastuszak,et al.  Drugs in pregnancy. , 1998, The New England journal of medicine.

[98]  E. Amon,et al.  A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy , 1987, Obstetrics and gynecology.

[99]  E. Widerlöv,et al.  Hydralazine-induced neonatal thrombocytopenia. , 1980, The New England journal of medicine.

[100]  V. Insler,et al.  Beta-adrenergic blocking agents in the treatment of pregnancy-induced hypertension. , 1995, International journal of clinical pharmacology and therapeutics.

[101]  M. Bennett,et al.  Phaeochromocytoma in pregnancy. , 1959, Lancet.

[102]  M. Brown,et al.  Hypertension in pregnancy: maternal and fetal outcomes according to laboratory and clinical features , 1996, The Medical journal of Australia.

[103]  F. Pipkin,et al.  The fetal outcome in a randomized double‐blind controlled trial of labetalol versus placebo in pregnancy‐induced hypertension , 1989 .

[104]  L. Impey Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks , 1993, British journal of obstetrics and gynaecology.

[105]  K. Lim,et al.  Urinary placental growth factor and risk of preeclampsia. , 2005, JAMA.

[106]  L. Magee,et al.  Do Commonly Used Oral Antihypertensives Alter Fetal or Neonatal Heart Rate Characteristics? A Systematic Review , 2004, Hypertension in pregnancy.

[107]  D. Altman,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[108]  H. Geijn,et al.  Calcium channel blockers in the management of preterm labor and hypertension in pregnancy. , 2001, European journal of obstetrics, gynecology, and reproductive biology.

[109]  K. Lim,et al.  Circulating angiogenic factors and the risk of preeclampsia. , 2004, The New England journal of medicine.

[110]  S. Bull,et al.  The generalizability of trial data; a comparison of beta-blocker trial participants with a prospective cohort of women taking beta-blockers in pregnancy. , 2001, European journal of obstetrics, gynecology, and reproductive biology.

[111]  C. Homer,et al.  Predicting Transformation from Gestational Hypertension to Preeclampsia in Clinical Practice: A Possible Role for 24 Hour Ambulatory Blood Pressure Monitoring , 2007, Hypertension in pregnancy.

[112]  A. Korda,et al.  Clonidine hydrochloride‐A safe and effective antihypertensive agent in pregnancy , 1985, Obstetrics and gynecology.

[113]  M. Brown,et al.  Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. , 2002, American journal of obstetrics and gynecology.

[114]  B. Psaty,et al.  Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. , 1995, Circulation.

[115]  G. Koren,et al.  The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. , 1996, American journal of obstetrics and gynecology.

[116]  L. Magee,et al.  Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis , 2003, BMJ : British Medical Journal.

[117]  B. Sibai,et al.  Chronic hypertension in pregnancy. , 1991, Obstetrics and gynecology clinics of North America.